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Abstract
Background: In obstructive congenital hydrocephalus, cerebrospinal fluid accumulation is associated with high
intracranial pressure and the presence of periventricular edema, ischemia/hypoxia, damage of the white matter, and
glial reactions in the neocortex. The viability and short time effects of a therapy based on bone marrow-derived
mesenchymal stem cells (BM-MSC) have been evaluated in such pathological conditions in the hyh mouse model.
Methods: BM-MSC obtained from mice expressing fluorescent mRFP1 protein were injected into the lateral
ventricle of hydrocephalic hyh mice at the moment they present a very severe form of the disease. The effect of
transplantation in the neocortex was compared with hydrocephalic hyh mice injected with the vehicle and non-
hydrocephalic littermates. Neural cell populations and the possibility of transdifferentiation were analyzed. The
possibility of a tissue recovering was investigated using 1H High-Resolution Magic Angle Spinning Nuclear Magnetic
Resonance (1H HR-MAS NMR) spectroscopy, thus allowing the detection of metabolites/osmolytes related with
hydrocephalus severity and outcome in the neocortex. An in vitro assay to simulate the periventricular astrocyte
reaction conditions was performed using BM-MSC under high TNFα level condition. The secretome in the culture
medium was analyzed in this assay.
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Results: Four days after transplantation, BM-MSC were found undifferentiated and scattered into the astrocyte
reaction present in the damaged neocortex white matter. Tissue rejection to the integrated BM-MSC was not
detected 4 days after transplantation. Hyh mice transplanted with BM-MSC showed a reduction in the apoptosis in
the periventricular neocortex walls, suggesting a neuroprotector effect of the BM-MSC in these conditions. A
decrease in the levels of metabolites/osmolytes in the neocortex, such as taurine and neuroexcytotoxic glutamate,
also indicated a tissue recovering. Under high TNFα level condition in vitro, BM-MSC showed an upregulation of
cytokine and protein secretion that may explain homing, immunomodulation, and vascular permeability, and
therefore the tissue recovering.
Conclusions: BM-MSC treatment in severe congenital hydrocephalus is viable and leads to the recovery of the
severe neurodegenerative conditions in the neocortex. NMR spectroscopy allows to follow-up the effects of stem
cell therapy in hydrocephalus.
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Background
In congenital hydrocephalus, there is an active accumu-
lation of cerebrospinal fluid with a prevalence of 4–6 in-
dividuals per 10,000 births [1, 2]. Clinically, it manifests
with ventriculomegaly (expansion of the cerebral ventri-
cles) and increased intracranial pressure [3], thus
adversely affecting brain tissue enclosed by the skull [4].
The main pathological consequences of congenital
hydrocephalus include damage to the cerebral white
matter, ischemia/hypoxia, inflammation, edema, and
gliosis [4–6]. There is no cure for congenital hydroceph-
alus, and presently, non-surgical therapies are not com-
pelling [7]. Thus, current treatments are surgical and
include ventricular shunts, extraventricular drains, or
third ventriculostomy. All of these treatments are merely
palliative and prevent some, but not all the associated
damages [4, 8]. Implantation of a ventricular shunt is the
most common treatment but presents frequent compli-
cations such as obstruction, infection, fracture, migra-
tion, overdrainage, or underdrainage [9, 10]. For this
reason, alternative strategies, such as stem cell therapies,
have been proposed hopeful in the treatment of hydro-
cephalus [11].
Mesenchymal stem cells (MSC) are considered an effi-
cient source for cell-based therapies in neurodegenerative
diseases. MSC can be purified from the bone marrow stro-
mal population based on the criteria that has been indicated
by the International Society for Cellular Therapy [12]. For
this study, following the criteria of isolation, a heteroge-
neous non-clonal culture of stromal cells that contains stem
cells with different multipotential properties committed
progenitors and differentiated cells has been obtained [12].
Therefore, in this study, the term MSC will actually con-
sider the stem cells referred to those conditions of isolation.
MSC expand efficiently in vitro, retain their multipotent
potential, and generate high cell quantities [13]. In experi-
mental therapies for chronic neurodegenerative diseases,
MSC provide functional improvements [14], which has
been attributed to their production of neurotrophins, re-
duction of oxidative stress, and modulation of inflammatory
responses [13, 14]. MSC also play a neuroprotective role by
creating favorable environments for regeneration producing
growth factors and cytokines and promoting vascularization
and remyelination [15].
Severe obstructive hydrocephalus concurs with the
physical deterioration of the neocortical white matter by
periventricular edema and astrogliosis [4, 16, 17]. Clin-
ical consequences at this stage include frequent shunt
failures that are difficult to treat [18]. We therefore
propose that intracerebroventricular administration of
bone marrow-derived MSC (BM-MSC) could provide
clinical benefits beyond the current standard of care.
The etiology of hydrocephalus that occurs in the hyh
mouse [19, 20] is similar to diverse forms of human
fetal-neonatal hydrocephalus [21–23]. This animal
model is compatible and comparable to hydrocephalic
infants undergoing complications [20, 24], exhibiting
similar neuropathological events such as myelin damage
and glial reactions [20].
Neuropathologically, in the hyh mouse, an obstruction
of the cerebral aqueduct [25] induces severe hydroceph-
alus by the post-natal first week and mortality within a
few more weeks [26]. The ventricular obstruction is moti-
vated by an alteration affecting the development of the
neuroepithelium covering the brain ventricles that lead to
ependymal lost and ventricular obstruction [27, 28].
Neuroepithelial developmental failure is a consequence of
the mutation in the Napa gene. This gene codifies the N-
ethylmaleimide-sensitive factor attachment protein alpha
(αSNAP) implicated in vesicular trafficking [27, 29].
Metabolite/osmolyte signatures have been previously
defined for various stages in the pathology of hydroceph-
alus [30] and serve as appropriate biomarkers in the pro-
gression of the disease.
The present research has evaluated the viability and
the therapeutic effect of BM-MSC therapy in severe
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congenital hydrocephalus by measuring metabolites/
osmolytes levels that are present in the neocortical par-
enchyma. For this purpose, 1H High-Resolution Magic
Angle Spinning Nuclear Magnetic Resonance (1H HR-
MAS NMR) spectroscopy [30] has been used.
Results have shown that 4 days following BM-MSC
intraventricular administration in hyh mice undergo-
ing very severe hydrocephalus, undifferentiated BM-
MSC are stabilized and mixed into the reactive astro-
cytes in the neocortex. A recovering in the neocor-
tical tissue of hyh mice treated with BM-MSC was
detected according to the levels of metabolites/osmo-
lytes and the reduction of periventricular apoptosis.
Due to the fact that most of the hyh mice with severe
hydrocephalus are not able to survive more than 5
weeks [26], the treatment was evaluated 4 days after
transplantation in 20-day-old mice. Thus, searching
effects of longer treatments was not viable.
We can conclude that BM-MSC treatment is feasible
and beneficial for severe hydrocephalus. Besides, spec-
troscopy could be transferable to clinical settings for
evaluating stem cell therapies in hydrocephalus.
Methods
Experimental animals
Transgenic homozygous male and female mice express-
ing the monomeric red fluorescent protein 1 (mRPF1;
Tg (GAG-mRPF1)aF1Hadj/J), of both sexes and 25 days
of age, were used to obtain the BM-MSC. Mutant hyh
mice (hydrocephalus with hop gait, B6C3Fe- a/a-hyh/J
strain), 20-day-old males and females with very severe
hydrocephalus according to Bátiz et al. [26], were used
to transplant BM-MSC (hydrocephalic hyh BM-MSC-
injected group) or sterile saline serum (hydrocephalic
hyh sham-injected group). Non-hydrocephalic litter-
mates at the same age were also used in the analysis of
some parameters (non-hydrocephalic control littermates
group, nh). Hyh and non-hydrocephalic mice were iden-
tified by phenotype inspection and genotyping [31]. All
mice were originally obtained from The Jackson Labora-
tory (Bar Harbor, ME, USA) and bred by the Animal Ex-
perimentation Service of the University of Malaga, in a
room at 22 °C with a 12:12 light/dark cycle, and standard
food and water available ad libitum. The design of the
experiments, housing, handling, care, and processing of
the animals were conducted in accordance with Euro-
pean and Spanish laws (RD53/2013 and 2010/63UE),
and following ARRIVE guidelines. According to current
legislation, experimental procedures (protocol # 4-2015-
A) were approved by the Institutional Animal Care and
Use Committee of the University of Malaga (CEUMA,
Spain) and the Regional Government Council (Junta de
Andalucía, Spain).
Bone marrow-derived mesenchymal stem cell isolation
and culture
Transgenic mRPF1 mice were sacrificed by cervical dis-
location to obtain the BM-MSC. Femurs were dissected
out, and bone marrow was flushed with a 29-gauge nee-
dle syringe (320924, BD Microfine, Madrid, Spain) con-
taining Dulbecco’s modified Eagle’s medium (DMEM,
Sigma-Aldrich, St Louis, MO, USA) supplemented with
1% penicillin/streptomycin, 0.5% amphotericin B, 6.25%
L-glutamine, and 10% fetal bovine serum (FBS, Sigma-
Aldrich). The suspension was centrifuged at 400g for 5
min. The cell pellet was suspended in 14ml of supple-
mented DMEM, plated on 75 cm2 flasks, and incubated
in a humidified incubator at 37 °C with 5% CO2. Twice
per week, the media were changed, and non-adherent
hematopoietic cells were removed. After 7–10 days,
when the culture was approximately 80% confluent, cells
were detached with trypsin/ethylenediaminetetraacetic
acid (EDTA; Sigma-Aldrich) and placed in new flasks.
After confluence, BM-MSC were detached and centri-
fuged and resuspended in saline serum at 10,000 cells/
μl. In some experiments, red fluorescent BM-MSC were
also labeled with a green cell tracker dye (C2925, Mo-
lecular Probes, Thermo Fisher, Waltham, MA, USA) be-
fore their transplantation. For that purpose, flasks were
rinsed with PBS and incubated with DMEM without
FBS for 30 min followed by incubation in green cell
tracker (1 μg/ml) for 30 min. There are variables that
could potentially affect the efficiency of treatment with
MSC. Thus, acute and chronic senescence has been re-
ported affecting BM-MSC under some culture condi-
tions [32]. These conditions were avoided in the
experiments carried out in the present study. BM-MSC
were always obtained from young transgenic mice. BM-
MSC were always cultured under the same conditions
and transplanted at passage 1 after reaching 70–80%
confluence. Cells were not cryopreserved and used im-
mediately. Immunogenicity, which is also relevant in
transplants with BM-MSC [33], was avoided as possible,
using allogenic transplants. Each experimental set was
performed using a transgenic mouse as a donor to a few
hydrocephalic hyh from the same litter or consanguin-
eous breeders. The same researcher performed the BM-
MSC isolations.
Scanning electron microscopy analysis
For scanning electron microscopy, BM-MSC were
placed in 13-mm-diameter non-coated coverslips. When
BM-MSC were approximately 80% confluent, they were
rinsed with phosphate buffer 0.1 M, pH 7.2 (PB), fixed
with 2% buffered glutaraldehyde (Electron Microscopy
Sciences, Hatfield, PA, USA), dehydrated in graded alco-
hol solutions, dried, and sputter-coated with gold.
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Flow cytometry analysis
BM-MSC from transgenic mRPF1 mice were detached
with trypsin/EDTA from flasks and suspended in ice-
cold Leibovitz’s L-15 medium (21083, Gibco, strepto-
mycin/streptomycin, 200 mg of bovine serum albumin
(BSA, A2058, Sigma-Aldrich), 1% HEPES, and 10% dis-
tilled H2O. BM-MSC suspensions (10
6 cells/ml) were in-
cubated for 30 min at 4 °C with fluorescent monoclonal
antibodies (see Table 1) in the supplemented L-15
medium. To detect intracellular antigens, BM-MSC were
detached as described above and fixed in 4% buffered
paraformaldehyde for 10 min. Then, fixed BM-MSC
were centrifuged and incubated with primary and fluor-
escent secondary antibodies as described below. For the
analysis of DNA content, fixed BM-MSC were incubated
with the nuclear dye 4′,6-diamidino-2-phenylindole
(DAPI; Molecular Probes, Eugene, OR, USA; 5 μg/ml). A
DakoCytomation MoFlo cytometer (Dako, Santa Clara,
CA, USA) and an FD FACSverse system (BD Biosci-
ences, Franklin Lakes, NJ, USA), calibrated according to
the manufacturer’s recommendations, were used for the
analysis. Fluorescence compensation was set using single-
stained controls, and matching median compensation al-
gorithms were applied. Data were analyzed using Summit
4.3.2. Software (Dako) and Kaluza Analysis Software
(Beckman Coulter, Indianapolis, IN, USA). Strategies in-
volving gating size versus granularity (forward scatter ver-
sus side scatter) and doublet exclusion were performed.
In vitro multilineage cell differentiation
Trilineage differentiation capacity was assessed for BM-
MSC. For adipogenic differentiation, BM-MSC were cul-
tured at a density of 3 × 105 cells/cm2 with DMEM 10%
FBS. Once confluence was reached, the culture medium
was replaced with adipogenic induction medium:
DMEM containing 10% FBS, 15% rabbit serum
(16120107, Gibco), 10−7 M dexamethasone, 0.5 mM 3-
isobutyl-1-methylxanthine, 10−9 M bovine insulin (I6634,
Sigma-Aldrich), and 0.2M indometacin. In cells fixed
with 4% paraformaldehyde, on days 4, 7, and 21, Oil Red
Table 1 Primary antibodies
Antibody Source Reference Type Use Dilution
Aquaporin-4 Sigma-Aldrich A5971 RbP FR 1:200
BDNF Abcam ab108319 RbM I, VB 1:250
CD11b BioLegend 101225 RtM FC 1:80
CD34 BioLegend 119309 MM FC 1:25
CD44 BioLegend 103015 MM FC 1:50
CD45.1 BioLegend 110713 MM FC 1:80
CD73 BD 561543 RtM FC 1:25
CD90.2 BioLegend 105315 RtM FC 1:200
Collagen type II Calbiochem-Novabiochem AB746P RbP C 1:40
F4/80 Biolegend 123107 RtM I, FC 1:200
GAPDH Abcam Ab9485 RbP WB 1:2500
GDNF Santa Cruz sc-328 RbP I, FC, VB 1:100
GFAP Sigma G-A-5 MM I, FC, VB, WB 1:1000
δGFAP Merck AB9598 RbP I 1:500
Glutamine synthetase Abcam Ab49873 RbP VB 1:5000
Iba1 Wako 019-19741 RbP FR, VB, WB 1:500, 1:1000 (WB)
Myeloperoxidase Abcam Ab139748 RbP VB 1:100
Nestin BIO-RAD AHP1739 RbP I, FC, VB 1:100
NeuN Merck MAB377 MM I, FC, VB 1:100
NG2 Merck AB5320 RbP I 1:200
NGF Abcam AB6199 RbP I, VB 1:500
RFP Chromotek 5F8 RtM FC, VB 1:500
β-III tubulin Promega A6712 MM I, FC 1:5000
VEGF Abcam Ab46154 RbP I, FC, VB 1:1000
Abbreviations: C BM-MSC in cell cultures, I immunofluorescence for BM-MSC on slides, FC flow citometry, FR frozen sections, MM mouse monoclonal, RbM rabbit
monoclonal, RtM rat monoclonal, RP rabbit polyclonal, VB vibratome sections, WB western blot. Sources: AbCam, Cambridge, UK; BD, San Diego, CA, USA;
BioLegend, San Diego, CA, USA; BIO-RAD, Oxford, UK; Chromotek, Planegg-Martinsried, Germany; GeneTex, Irvine, CA, USA; Merck Millipore, Burlington, MA, USA;
Promega, Madison, WI, USA; Santa Cruz Biotechnology, Dallas, TX, USA; Sigma-Aldrich
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O staining was used to detect lipid vacuoles (indicative
of adipogenic differentiation). Chondrogenic differenti-
ation was assayed using suspensions of 106 cell/ml to
form 3D pellets in conical tubes with DMEM supple-
mented with 10−7 M dexamethasone, 1% ascorbate-2-
phosphate, 1% insulin-transferrin-selenium (ITS) + Pre-
mix Tissue Culture Supplement (354352, Corning, New
York City, NY, USA), 1 mM sodium pyruvate, 1% MEM
non-essential amino acid solution (Sigma, M7145), and
10 ng/ml recombinant human transforming growth
factor-beta 1 (rhTGF-β1, 240-B, R&DSystems, Minneap-
olis, MN, USA). Pellet culture without rhTGF-β1 was
used as negative control. After 21 days, pellets were fixed
with 10% of neutral buffered formalin. Then, they were
dehydrated in alcohol, embedded in paraffin, and sec-
tioned at 10 μm thick. To detect cartilage matrix, indi-
cating chondrogenic differentiation, collagen type II was
immunodetected, after hydration of the paraffin sections,
using an appropriate antibody (Table 1) followed of a bi-
otinylated secondary antibody, ExtrAvidin-peroxidase
(diluted 1:2000; E2886, Sigma), and 3,3′-diaminobenzi-
dine tetrahydrochloride (DAB; Sigma; 0.1%) as chromo-
gen. Then, sections were dehydrated and mounted.
Sections were also stained with Toluidin Blue, Blue
Alcian, and Safranin O-Fast Green to check the meta-
chromatic reaction of the cartilage matrix. For osteogenic
differentiation assay, BM-MSC were cultured at a 3 × 103
cells/cm2 density with DMEM + 10% FBS. When cultures
were approximately 80% confluent, the medium was sup-
plemented with 10−8M dexamethasone, 50 μM ascorbate-
2-phosphate, and 2mM β-glycerophosphate. Alkaline
phosphatase (ALP) histochemistry/fluorometry (for details
of the procedures, see [34]) and Alizarin Red S staining
were used to detect calcium deposition on days 7, 14, and
21 after induction. In the adipogenic and osteogenic dif-
ferentiation assays, BM-MSC with only DMEM + 10%
FBS were cultured for negative control. For the chondro-
genic assay, pellet culture without rhTGF-β1 was used as
the negative control.
Bone marrow-derived mesenchymal stem cell
characterization
BM-MSC were detached with trypsin/EDTA, centrifuged
at 400g for 5 min, and fixed in 2% buffered paraformal-
dehyde for 10 min. Then, BM-MSC were placed on
slides, dried at room temperature, and processed for im-
munofluorescence as described below. More than 7000
BM-MSC were analyzed in these conditions.
Bone marrow-derived mesenchymal stem cell
transplantation
Procedures were performed under 3% sevoflurane in 1 l/
min of oxygen anesthesia in an adapted stereotaxic in-
strument. A hole (1 mm diameter) was drilled in the
skull covering the distinguishable enlarged right lateral
ventricle of hydrocephalic hyh mice. Then, a 20-μl cell
suspension containing 200,000 BM-MSC was injected
into the ventricle with a peristaltic pump at 10 μl/min.
The needle was left 2 min more before removing, and fi-
nally, the skin was closed. A group of hyh hydrocephalic
mice (hydrocephalic hyh sham-injected) were injected
following the same procedure with vehicle solution (sa-
line) but no cells.
1H HR-MAS NMR spectroscopy
Non-hydrocephalic mice (n = 20), hydrocephalic hyh
mice transplanted with BM-MSC (n = 10), and hydro-
cephalic hyh sham-injected mice (n = 9) were sacrificed
by cervical dislocation. The neocortex of the right and
left hemispheres was quickly removed under cold condi-
tions, frozen on dry ice, and stored at − 80 °C. 1H HR-
MAS NMR spectroscopy was used to analyze the meta-
bolic profiles of dissected samples from the right hemi-
spheres following the previously described methodology
[30]. Spectra were obtained in a 600-MHz Bruker
Avance Spectrometer (Bruker BioSpin, Ettlingen,
Germany), at 4 °C and a 5-kHz spinning rate.
RT-PCR
The neocortex of the left hemispheres from the same
mice used for 1H HR-MAS NMR spectroscopy and non-
injected hydrocephalic hyh mice (without any surgery,
n = 7) was used to extract total RNA with Tripure Isola-
tion Reagent (Roche, Basel, Switzerland). Contaminating
DNA was removed using DNAase (Sigma-Aldrich). Ret-
rotranscription of 3 μg of total RNA was performed with
the High-Capacity cDNA Reverse transcription Kit
(4374967, Applied Biosystems, Foster City, CA). For RT-
PCR, 40 ng of cDNA was mixed with Eagle Taq Master
Mix (Sigma-Aldrich) and TaqMan Gene Expression
assay probes (IL-1α Mm01336161_m1, IL-1β
Mm00434228_m1, IL-10 Mm00439614_m1, CD45
Mm01293577_m1, GFAP Mm01253033_m1, iba1
Mm00479862_gl, and Ki67 Mm01278617_m1; Applied
Biosystems). Quantification was performed with an ABI
Prism 7000 Sequence Detector System (Applied Biosys-
tems). Results were expressed using the comparative
double-delta Ct method (2-ΔΔCt). ΔCt values represent
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
normalized expression levels and non-hydrocephalic
mice as a control condition. In all cases, the slopes of
the curves indicated optimal PCR conditions (slopes of
3.2–3.4).
Western blot analysis
The neocortex from the same mice used for metabolite
and RT-PCR analysis was also used for the western blot
analysis. Total protein was extracted using RIPA buffer
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with a protease inhibitor cocktail (P8340, Sigma-Aldrich)
for 10 min at 4 °C. Then, samples were centrifuged at
8000g for 10 min at 4 °C. Proteins from the supernatant
were quantified with the Bradford assay and separated
on a one-dimensional SDS-polyacrylamide gel electro-
phoresis, transferred to a 0.45-μm-pore-diameter nitro-
cellulose membrane Amersham PROTAN (Sigma-
Aldrich) in a SemiDry TRANS-BLOT (BIO-RAD,
Hercules, CA, USA), incubated with the primary anti-
bodies (see Table 1), and then in HRP-conjugated sec-
ondary antibodies (Sigma-Aldrich). Immunoreaction was
visualized with a chemiluminescent substrate (ECL, Cell
Signalling, Danvers, MA, USA) and imaged using Che-
miDoc XRS+ (BIO-RAD). GAPDH was used as a protein
loading control and non-hydrocephalic mice as a control
condition.
Immunofluorescence
Mice (hydrocephalic sham-injected mice, n = 11; hydro-
cephalic hyh mice transplanted with BM-MSC, n = 12;
non-hydrocephalic mice, n = 5) were sacrificed under
anesthesia with Dolethal (sodium pentobarbital; Véto-
quinol, Lure, France; intraperitoneal administration, 0.2
mg/g body weight) and transcardially perfused with 4%
buffered paraformaldehyde. Fixed brains were removed
and post-fixed in the same solution for 24 h at 4 °C. The
brains were sectioned with a vibratome (80-μm-thick
sections) or were cryoprotected in 30% sucrose to obtain
frozen sections (60-μm-thick). Type of sections and
thickness were selected accordingly to obtain the best
immunolabeling depending on the used antibodies and
to maintain the section integrity. Sections of brains and
slides containing isolated BM-MSC were immunostained
with specific primary antibodies and appropriate fluores-
cent secondary antibodies (Table 1), using DAPI as nu-
clear staining, and mounted in Vectashield (Dako,
Glostrup, Denmark).
Apoptosis analysis
Additional groups of experimental mice (hydrocephalic
hyh sham-injected mice, n = 6; hydrocephalic hyh mice
transplanted with BM-MSC, n = 5) were sacrificed and
fixed as described above for immunofluorescence. Brains
were cryoprotected in 30% sucrose to obtain 60-μm-
thick frozen sections. Apoptotic cells in the neocortex
were detected using a TUNEL assay (ab206386, Abcam,
Cambridge, UK) according to the manufacturer’s
instructions.
In vitro assay of bone marrow-derived mesenchymal stem
cells under TNFα conditions
BM-MSC in P1 (70–80% confluence) were plated in
DMEM (supplemented with 1% penicillin/streptomycin,
0.5% amphotericin B, and 6.25% L-glutamine) containing
50 ng/ml TNFα (cyt-252-a; Prospec, Ness-Ziona, Israel)
and incubated for 24 h with 5% CO2 at 37 °C. Two control
conditions were used: (i) C1, incubated in DMEM with no
TNFα and supplemented with 1% penicillin/streptomycin,
0.5% amphotericin B, and 6.25% L-glutamine; (ii) C2, in-
cubated in same culture medium used for C1 but supple-
mented with additional 10% FBS. After incubation, media
from the different conditions were frozen at − 80 °C and
stored until cytokine and mass spectrometry analyses were
performed.
Cytokine analysis of culture media
Culture media from BM-MSC with TNFα and the con-
trols C1 and C2 were incubated on membranes for a
mouse 62 cytokines antibody array (Abcam, AB133995)
and processed according to the manufacturer’s instruc-
tions. Densitometry data was calculated using Image Lab
software (BIO-RAD) and normalized in base to C1 con-
trol. A heat map for cytokine expression (densitometry)
was obtained using http://heatmapper.ca [35]. The PAN-
THER Classification System (v.14.1) [36] and DAVID
Bioinformatic Resources (6.8) [37] were used to detect
the main biological processes related to the overex-
pressed proteins.
Mass spectrometry analysis of the secretome in the
culture media
Peptide analysis of the culture media samples from BM-
MSC under TNFα and C1 conditions (3 samples each
condition) was carried out by quadrupole-orbitrap nano-
HPLC-ESI-MS/MS. Culture media was lyophilized and
dissolved in water. Gel-assisted proteolysis was per-
formed for the proteins entrapped in a polyacrylamide
gel matrix. Protein digestion and sample preparation
were carried out using DigestPro MSI (INTAVIS Bioa-
nalytical Instruments AG, Cologne, Germany). Peptides
were purified and concentrated using C18 ZipTip
(Merck Millipore) according to the manufacturer’s in-
structions. Samples were injected into an Easy nLC 1200
UHPLC system coupled to a Q Exactive™ HF-X Hybrid
Quadrupole-Orbitrap Mass Spectrometer (Thermo-
Fisher). Data was acquired using Tune 2.9 and Xcalibur
4.1.31.9 (ThermoFisher). Swiss-Prot database was used
to identify Mus musculus proteins. These proteins were
analyzed using Proteome Discoverer 2.2 (Thermo Fisher)
and the tandem mass spectrometry data analysis pro-
gram SEQUEST. The false discovery rate (FDR) was cal-
culated using Percolator. Minora feature detector in
Proteome Discoverer 2.2 (Thermo Fisher) was used for
the label-free quantification.
Image analysis and quantification
Immunofluorescence images were obtained with Leica
SP5 II and SP8 laser confocal microscopes (Leica,
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Wetzlar, Germany). For each experiment, images were
obtained in batches using the same settings. Figures
were composed using Adobe Photoshop CS5.1, and the
same minimal changes in brightness and contrast were
applied. The densities (cells/area) of GFAP+, Iba1+,
NG2+, Olig2+, and NeuN+ cells were calculated in 4
fields in each parietal cortex section (2-μm-thick con-
focal planes) per animal. Western blot images obtained
with ChemiDoc XRS+ were quantified using ImageJ soft-
ware (NIH, USA). Densities of apoptotic cells were
quantified in bright-field micrographs obtained by scan-
ning under a VS120 microscope (Olympus, Tokyo,
Japan) with an UPLSAPO20x/0.75 objective, and then
processed with ImageJ software. The whole periventricu-
lar areas of 3 sections per animal (60-μm-thick sections)
were used for quantification of TUNEL+ nuclei.
Statistics
Statistical analyses were performed using KaleidaGraph
(Synergy Software, Reading, PA, USA) and Statgraphics
Centurion XVII (Statpoint Technologies, Warrenton,
VA, USA). The required sample size was estimated ac-
cording to standard deviations or significances with a
minimum of 30 freedom degrees. Animals were num-
bered without indication of the group. Data collection
and analyses were blinded by using different researchers
and by masking the samples. All values are reported in
the figures as mean with 95% confidence. The
Wilcoxon-Mann-Whitney test and Student’s t test were
applied for hypothesis testing in situations requiring
non-parametric and parametric analyses, respectively.
When the F probability from Student’s t test was < 0.05,
the variance was considered unequal. P < 0.05 based on
both tests was considered statistically significant.
A logistic regression analysis was carried out to iden-
tify the differential metabolite profiles that distinguish
both groups of hydrocephalic hyh mice (treated with
BM-MSC and sham-injected). A prediction exponential
function was obtained. The relationship between the
variables Xn and P is non-linear, and the parameters Bn
were estimated using the logistic regression algorithm.
Larger Bn values indicated a larger impact of the vari-
ables Xn.
P v ¼ 2½  ¼ exp B0 þ B1X1 þ…þ BnXnð Þ=1
þ exp B0 þ B1X1 þ…þ BnXnð Þ
Z ¼ B0 þ B1X1 þ…þ BnXn
P is the predicted probability of a given sample to be
classified in 1 of the 2 defined groups (BM-MSC and
sham). V is the variable of the group and indicates 1 of
the 2 groups analyzed.
In PANTHER and mass spectrometry analyses, P value
calculation is indicated in the tables.
Results
Multipotentiality and characterization of the BM-MSC
BM-MSC from mRFP1 transgenic mice were grown in
primary cultures until forming a large number of
colony-forming units (Fig. 1a). On secondary cultures,
BM-MSC retained their red fluorescence and appeared
as spindle-shaped cells (Fig. 1b, c).
In order to confirm the identity of the isolated BM-MSC
as multipotential cells [38], their trilineage differentiation
was assayed through adipocytes, chondrocytes, and osteo-
cytes. Adipogenic differentiation was confirmed by the
presence of lipid droplets after 14 days with adipogenic-
inducing culture medium (Fig. 1d). The 3D pellet culture
showed that BM-MSC were able to differentiate into chon-
drocytes, exhibiting a cartilaginous matrix with collagen
type II (Fig. 1e) and metachromasia. After osteogenic in-
duction for 21 days, BM-MSC formed white nodule-like ag-
gregations. Their mineralization was stained with alkaline
phosphatase (ALP, Fig. 1f) and Alizarin Red. In osteoin-
ducted cells, ALP activity was higher when compared to
control cells (Fig. 1g). As a control, in the three lineages,
non-supplemented cells were negative for all staining.
Flow cytometry analysis showed that non-fixed BM-
MSC were positive for the mesenchymal markers [38]
CD44, CD73, and CD90 (Fig. 1h, Additional file 1), and
negative for the expression of the hematopoietic markers
[38] CD34 and CD45 (Fig. 1i, Additional file 1). The
analysis of the primary cell culture revealed that ap-
proximately 10% of the cells were positive for CD11b
and F4/80 markers (Additional file 2). These profiles can
be explained based on the analysis in the culture condi-
tions and the cell passage (passage 1 in this case) [39].
The DNA content of BM-MSC was stained with DAPI
and analyzed with flow cytometry (Fig. 1j). Proportions
of cells in the different cycle phases were 89.2% in G1
(unreplicated complement of DNA), 4.3% in G2 and M
phase (fully replicated complement of DNA), and 6.5%
in S phase (intermediate amount of DNA). The presence
of polyploid cells was discarded with DAPI staining in
flow cytometry.
To characterize BM-MSC before their application in
the hydrocephalic hyh mice, analyses of fixed cells by
flow cytometry and immunofluorescence in slides were
carried out (Fig. 1k–m). BM-MSC presented an eccen-
tric kidney-shaped nucleus. BM-MSC were found ex-
pressing some neural stem cell markers, such as the glial
fibrillary acidic protein delta (δGFAP), nestin, or
neuron/glial antigen 2 (NG2). BM-MSC also expressed
αGFAP (astrocyte marker). These markers were present
in almost all the analyzed cells. On the other hand, only
a few BM-MSC were labeled for β-III tubulin (neuro-
blast marker), and none for NeuN (mature neuron
marker; Fig. 1m). Besides, BM-MSC were confirmed ex-
pressing neuroprotector factors (Fig. 1m), such as the
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glial cell-derived neurotrophic factor (GDNF), the neural
growth factor (NGF), the brain-derived neurotrophic
factor (BDNF), and the vascular endothelial growth fac-
tor (VEGF).
Homing of the BM-MSC into the damaged periventricular
walls
One day after injection, BM-MSC were confirmed to
have entered the periventricular parenchyma at regions
Fig. 1 Characterization of BM-MSC before transplantation into hydrocephalic hyh mice. a BM-MSC primary culture forming a colony unit. Phase-
contrast microscopy. b BM-MSC expressing the mRFP1 (red). Merge of phase-contrast and epifluorescence microscopies. c Spindle-shaped BM-
MSC under scanning electron microscopy. d Oil Red O staining of lipid droplets (arrows) in the cytoplasm of BM-MSC after adipogenic
differentiation for 14 days. Merge of phase-contrast and bright-field microscopy images. e Collagen type II immunostaining of a 3D pellet culture
of BM-MSC after 21 days of chondrogenic differentiation. f Osteoinducted BM-MSC stained with alkaline phosphatase (ALP) 21 days after
induction. g ALP activity in control (black) and osteoinducted (gray) BM-MSC at 7, 14, and 21 days. h, i Representative immunophenotype profiles
of unfixed BM-MSC for CD44 and CD34 markers by flow cytometry. j Flow cytometry analysis of DNA content (DAPI fluorescence) in fixed BM-
MSC. k, l Detection of a neural cell marker (GFAP) and a neuroprotector factor (GDNF) in fixed BM-MSC by flow cytometry. m
Immunofluorescence (green) in fixed BM-MSC before injection for δGFAP, nestin, NG2, αGFAP, β-III tubulin, NeuN, GDNF, NGF, BDNF, and VEGF. In
the absence of labeling, the channel for red (RFP fluorescence) is also shown. Nuclear staining with DAPI (blue). Negative control represents the
omission of the primary antibodies. **P < 0.02, ***P < 0.01 Wilcoxon-Mann-Whitney test
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where astrocyte reaction was not compactly developed
(Fig. 2c; for a description of these regions, see [40]). Ex-
cepting this confirmation, the whole results below are
referred to mice analyzed 4 days after injection of the
BM-MSC. Four days after intraventricular injection,
BM-MSC were found integrated into the damaged areas
of the periventricular parenchyma in both lateral ventri-
cles in hyh mice (Fig. 2a). Because neocortical walls, and
in particular the white matter, are the more affected
areas in hydrocephalus of human and animal models
[20, 21, 30, 41–43], the analysis of the results was fo-
cused into this region.
In fixed brain sections, BM-MSC were detected by red
fluorescence from donor mRFP1 expression and green
fluorescence from the cell tracker dye applied in vitro
before injection (Fig. 2a), as well as immunolabeling with
an antibody recognizing mRFP1 (Fig. 2b). Thus, 4 days
after transplantation, BM-MSC were located in the neo-
cortical walls within the layer of reactive astrocytes cov-
ering the denuded ependyma surface (for a description
of these regions, see [20, 40, 44]), around the blood ves-
sels, and intermixed with the diffuse reactive astrocytes
in the white matter (Fig. 2d). Transplanted BM-MSC
expressed the stem cell marker nestin (Fig. 2e) and also
presented a weak expression of GFAP compared to
neighboring reactive astrocytes (Fig. 2e). The BM-MSC
were also found expressing the neuroprotector factors
GDNF, BDNF, and VEGF in the same way as in vitro be-
fore injection (Fig. 2f–h).
Effects on inflammatory conditions and glial reactions
In order to be a possible treatment, introduction of the
stem cells should not induce extensive inflammatory re-
sponses in animals already compromised. Thus, to evalu-
ate possible immunological rejection, the expression of
inflammatory interleukins (IL-1α, IL-1β) was analyzed in
four groups of mice: hydrocephalic hyh treated with
BM-MSC, hydrocephalic hyh sham-injected, hydroceph-
alic hyh non-injected (hyh without any surgery), and
non-hydrocephalic (without any surgery). Other cyto-
kines such as the tumor necrosis factor alpha (TNFα)
were not considered for analysis because a previous re-
port in hyh mice indicated they would already be raised
according to their etiopathology [43]. Levels of the inter-
leukins were higher in BM-MSC-injected and sham-
injected hydrocephalic hyh mice than in the non-
hydrocephalic mice or non-injected hydrocephalic hyh
mice (Fig. 3a, b). These results indicate that surgical pro-
cedure induces high IL levels. These results also suggest
that non-injected animals are not an appropriated con-
trol to evaluate BM-MSC inflammatory response in the
injected hydrocephalic hyh mice. However, we can effi-
ciently compare hydrocephalic injected and non-injected
hyh mice to determine inflammatory reaction in the
presence of BM-MSC. Interleukin levels in hydroceph-
alic hyh mice with BM-MSC were not significantly dif-
ferent from hydrocephalic hyh sham-injected mice.
Levels of the anti-inflammatory interleukin IL-10 were
negligible in all the groups of mice, including the BM-
MSC treated one. Thus, in the present study and condi-
tions, the presence of an anti-inflammatory effect cannot
be concluded.
Microglia reaction was studied by expression of iba1
(mRNA and protein; microglia marker) and CD45
(mRNA; activated microglia marker). Hydrocephalic hyh
mice (BM-MSC-treated and sham-injected) had upregulated
CD45 and iba1 levels compared to non-hydrocephalic mice.
In contrast, no differences in CD45 and iba1 levels were
found between BM-MSC-injected and sham-injected mice
(Fig. 3c–e). In the same way, the densities of iba1 immunore-
active cells in the neocortex were similar between hyh mice
transplanted with BM-MSC and sham-injected (Fig. 3f, g).
Activated microglia (CD45 labeling) or neutrophils (myelo-
peroxidase labeling) were not detected in the neighborhood
of the BM-MSC. Analysis of astrocyte reactivity using the
GFAP marker did not reveal any difference between the two
groups of hydrocephalic hyh mice, BM-MSC-injected and
sham-injected (Fig. 3h–k). The similar levels of Ki67 mRNA
in the neocortex of hydrocephalic hyh mice treated with
BM-MSC and sham-injected (Additional file 3) support the
absence of glial reactions or uncontrolled proliferation of
BM-MSC. Transplanted BM-MSC were not detected form-
ing clusters but were found spared in the white matter and
astroglial reactions.
Effects of transplanted BM-MSC into the different neural
cell populations
In order to confirm that BM-MSC do not transdiffer-
entiate after transplantation, an immunohistochemical
characterization of the integrated BM-MSC was carried
out. In the neocortex, there was no increase in the dens-
ities of neural cell populations due to BM-MSC treat-
ment, thus suggesting an absence of new neuronal cells
or transdifferentiation of the BM-MSC. The densities of
NG2+ (oligodendrocyte progenitors), Olig2+ (oligoden-
drocytes), and NeuN+ (mature neurons) cells were simi-
lar between hydrocephalic hyh mice treated with BM-
MSC or sham injection (Fig. 3l–p). The density of ma-
ture neurons in the different neocortical layers was simi-
lar between both groups of hydrocephalic mice, treated
with BM-MSC and sham-injected (Fig. 3o, p). Trans-
planted BM-MSC were immunonegative for the enzyme
glutamine synthetase, which should only be present in
astrocytes (Fig. 3q). BM-MSC were weakly labeled with
anti-NG2, unlike oligodendrocyte progenitors that ex-
hibited strong immunolabeling (Fig. 3r). A few BM-MSC
were weakly stained with β-III tubulin (Fig. 3s), in con-
trast to the strongly labeled neuroblasts. These patterns
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Fig. 2 (See legend on next page.)
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of immunostaining of the BM-MSC integrated into the
brain parenchyma resembled the state of these cells
in vitro before injection (Fig. 1m).
Reduction of apoptosis
Because BM-MSC have been associated with neuropro-
tective roles [13, 45], the density of apoptotic cells in
host tissues was analyzed by TUNEL labeling. In hydro-
cephalic hyh mice treated with BM-MSC, the number of
apoptotic cells was reduced by 50% compared to sham-
injected hyh mice (Fig. 4a). In both cases, the location of
apoptotic cells as seen by TUNEL+ chromogenic label-
ing was mainly observed within the damaged periven-
tricular surfaces (Fig. 4b, c).
Reduction in the levels of osmolytes
Possible recovery of the neocortical tissue was investi-
gated by analyzing the metabolic state of the neocortex
by 1H HR-MAS NMR spectroscopy in ex vivo samples.
Many metabolites are significantly increased under con-
ditions of congenital hydrocephalus in hyh mice and in-
dicate pathological severity [30]. Metabolites/osmolytes
to be studied were selected based on standard human
clinic NMR practices and according to a previous study
in the hyh mouse [30]. Four days after BM-MSC
implantation, creatine, glutamate, glycine, phosphatidyl-
ethanolamine, and taurine were found at lower concen-
trations in the hydrocephalic hyh transplanted with BM-
MSC compared to hydrocephalic hyh mice sham-
injected mice (Fig. 5a–e). Interestingly, BM-MSC treated
mice exhibited recovered metabolite levels similar to
non-hydrocephalic mice (Fig. 5a–e). While levels of glu-
tamine and threonine were also reduced in hydroceph-
alic hyh mice treated with BM-MSC compared to
hydrocephalic hyh sham-injected mice (Fig. 5f, g), they
did not recover entirely back to non-hydrocephalic
levels. In the case of N-acetyl-aspartate and GABA, while
hydrocephalic hyh mice exhibited significantly increased
levels, the BM-MSC treatment still reduced the levels of
these metabolites (Fig. 5h, i). Other metabolites did not
present significant differences in their levels according
to the trends described above (Additional file 4). Logistic
regression analysis for the discrimination of both groups
of hydrocephalic hyh mice (BM-MSC-injected and
sham-injected) showed that the combination of creatine,
glutamate, N-acetyl-aspartate, taurine, and threonine
had the highest predictive score that allows correct dis-
crimination between the two groups of hydrocephalic
hyh mice, treated with BM-MSC and sham-injected
(Table 2).
In vitro cytokine secretion from BM-MSC stimulated with
TNFα
To elucidate the mechanisms that could be associated
with BM-MSC integration into the astrocyte reaction
and tissue recovering, an in vitro analysis was performed
after incubation of the BM-MSC with TNFα. Our previ-
ous studies have proved that there are high levels of
TNFα in the periventricular astrocyte reaction in hyh
mice [43]. Thus, the secretome of BM-MSC under the
presence of TNFα was investigated. VEGF and several
cytokines were found upregulated under TNFα incuba-
tion (Fig. 6, Tables 3 and 4, Additional file 5). According
to the database, such upregulation can be implicated in
angiogenesis, endothelial permeability, locomotion, cell
movement, and the orchestration of inflammatory and
immune responses.
Discussion
Integration of BM-MSC into the damaged periventricular
walls without rejection
BM-MSC transplanted into the ventricles of hydroceph-
alic hyh mice exhibited successful migration toward sites
of damaged brain tissue and dispersed into the neocor-
tex periventricular zones that were presenting ischemia,
interstitial edema, axonal damage, and astrocyte reactiv-
ity [4, 20, 41, 46, 47]. The BM-MSC presumably were
attracted by chemokines [13, 48] and TNFα [49], the lat-
ter of which has been proposed to be upregulated and
released by the periventricular reactive astrocytes in the
hyh mouse [43].
In young, healthy mice, it has been reported that MSC
administered intracerebroventricularly form cell clusters
attached to the ventricle walls [50]. However, in the
(See figure on previous page.)
Fig. 2 Location of BM-MSC in the hosting tissue and detection of neuroprotector factors expression. a Walls of the lateral ventricle of a hyh
mouse administered at 20 days of age with BM-MSC expressing the mRFP1 (red) and labeled with a green cell tracker (white arrows), 4 days post-
injection (dpi). a’ Detail of a BM-MSC (RFP fluorescence, red) colabeled with the fluorescent green cell tracker (white arrow). b, b” Colabeling of
the mRFP1 (red) with an antibody against RFP (green) in the administered BM-MSC, 4 dpi, in the neocortex of a hyh mouse injected at 20 days of
age. c BM-MSC (red, white arrows) entering into the brain parenchyma of a hyh mouse 20 days of age, 1 dpi, through a ventricle surface
presenting a loose periventricular layer of reactive astrocytes (GFAP immunolabeling, green) in the neocortex wall. d In the neocortex walls of
hyh injected at P20, BM-MSC were found in three different locations at 4 dpi: between the dense layer of reactive astrocytes covering the
ventricle surface (arrowhead, GFAP immunolabeling in green), around the blood vessels (arrow), and deep into the brain parenchyma (asterisk).
e–e”’ Coexpression in BM-MSC (mRFP1, red; arrows) at 4 dpi in the neocortex wall of GFAP (magenta) and nestin (green). f–f”’ Coexpression at 4
dpi in BM-MSC (red mRFP1, arrow) of GFAP (magenta) and GDNF (green). g–g”’ BM-MSC (mRFP1, red; arrow) colabeled with the green cell
tracker and anti-BDNF (magenta) at 4 dpi. h–h”’ Expression in BM-MSC (red, mRFP1; arrows) of VEGF (green) at 4 dpi
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Fig. 3 Levels of proinflammatory cytokines and densities of neural cells. a, b Levels of mRNA of interleukins IL-1α and IL-1β in the groups of
mice: non-hydrocephalic (nh), hydrocephalic hyh non-injected (hni), hydrocephalic hyh sham-injected (sham), and hydrocephalic hyh BM-MSC-
treated (BM-MSC). c–f Levels of mRNA, protein, and cell densities for CD45 and iba1 as microglia markers. g, g’ Immunofluorescence for iba1 in
the neocortex of a hydrocephalic hyh mouse treated with BM-MSC and in a hydrocephalic hyh sham-injected mouse. h–j Levels of mRNA,
protein, and cell densities for the GFAP astrocyte marker. k, k’ Immunofluorescence for GFAP in the neocortex of a hydrocephalic hyh mouse
treated with BM-MSC and in a hydrocephalic hyh sham-injected mouse. l, m Densities of NG2+ and Olig2+ cells in tissue sections. n, n’
Immunofluorescence for NG2 (green) and Olig2 (red). o Densities of NeuN+ cells in sections of the neocortical layers 2–3 and 5. p, p’
Immunofluorescence for NeuN (green) in the neocortex. q Immunofluorescence for glutamine synthetase. The BM-MSC (mRFP1, red) present no
reaction for glutamine synthetase (arrows). r Immunofluorescence for NG2. The BM-MSC present a weak immunoreaction (arrows) compared to
NG2 cells (arrowheads). s Immunofluorescence for β-III tubulin (magenta) in BM-MSC (mRFP1, red) labeled with the green cell tracker in the
neocortical wall. Arrowhead points to a β-III tubulin negative BM-MSC. Insets in r and s represent splitting of the channels showing
immunolabeling for NG2 and cell tracker (green) and β-III tubulin (magenta) in the framed red fluorescent BM-MSC. *P < 0.05, ***P < 0.02, ***P <
0.01 Wilcoxon-Mann-Whitney test
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present study, BM-MSC never formed clusters. In con-
trast, they were found spread throughout the cerebral
ventricle walls. Two explanations can be given for such a
difference: first, the five times smaller number of MSC
(200,000/animal) applied in the present investigation
compared with Jungwirth’s study (1,000,000/animal);
secondly, the pathological environment present in the
brain of the hydrocephalic hyh mouse. In any case,
the number of cells applied in the present study is
sufficient to produce favorable effects in severe hydro-
cephalus, without forming such clusters or adverse ef-
fects. Nevertheless, the number of cells to transplant
Fig. 4 Densities of apoptotic cells in the neocortex. a TUNEL+ cells in hydrocephalic hyh mice treated with BM-MSC and hydrocephalic hyh
sham-injected mice, 4 dpi. ###P < 0.01 Student’s t test. b, c Periventricular apoptotic cells (arrows) in a hyh mouse administered with BM-MSC cells
and in a hydrocephalic hyh sham-injected mouse. c’ Detail of an apoptotic cell shown in the area framed in c
Fig. 5 Levels of metabolites in the neocortex. Analysis was carried out in non-hydrocephalic mice, hydrocephalic hyh mice transplanted with BM-MSC,
and hydrocephalic hyh sham-injected mice, 4 dpi. *P < 0.05, **P < 0.02, ***P < 0.01 Wilcoxon-Mann-Whitney test; ##P < 0.02, ###P < 0.01 Student’s t test
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Fig. 6 Heat map showing the relative concentrations of cytokines secreted by BM-MSC stimulated with TNFα. C1, control without TNFα. C2, equal
to C1 with the addition of 10% FBS. Cytokines were detected using an array. Colors were assigned according to the relative scale of expression.
Z = 0 represents the mean value
Table 2 Logistic regression analysis for the discrimination between hyh mice treated with BM-MSC and hydrocephalic sham-injected mice
Metabolite B Standard error Wald df P value* eB Lower Upper
Creatine 0.972 0.489 3.961 1 0.047* 2.644 1.015 6.891
Glutamate 0.657 0.300 4.803 1 0.028* 1.929 1.072 3.471
N-acetyl-aspartate 1.086 0.496 4.781 1 0.029* 2.961 1.119 7.835
Threonine 3.989 1.965 4.121 1 0.042* 54.007 1.147 2542.003
Taurine 0.467 0.226 4.249 1 0.039* 1.595 1.023 2.485
For each metabolite, the following are shown: B, equation coefficient; standard error; Wald-test statistics; df, degrees of freedom; P value; exponential of B;
and the lower and upper confident intervals
*P value significant
García-Bonilla et al. Stem Cell Research & Therapy          (2020) 11:121 Page 14 of 20
should be taken into account for the clinical applica-
tion of MSC.
MSC produce factors that affect the maturation and
function of immune cells, suppressing innate and adap-
tive immunity [49]. However, in a study with BM-MSC
injected into the parenchymal tissue of mature, healthy
rats, stem cells have been found missed after 14 days,
which was interpreted as a rejection [51]. It must be
considered that MSC would either suppress or promote
inflammation according to the milieu where they are ap-
plied [49]. Thus, anti-inflammatory effects would take
place during the late phase of inflammation [49]. In the
present study, the presence of inflammatory conditions
in hyh mice before transplantation with BM-MSC
(present results, see in [43]) would support the ab-
sence of rejection. The absence of rejection in treated
hyh mice is evidenced by the lack of recruited neu-
trophils, macrophages, or activated microglia in the
areas where BM-MSC are integrated 4 days after in-
jection. Besides, there was no increase in the astrocyte
reaction at this time.
Absence of transdifferentiation of the transplanted BM-
MSC
There is controversy regarding the possibility of the
transdifferentiation of MSC into neural cells [52]. It has
Table 3 Over-represented biological processes of the BM-MSC secretome under TNFα compared with control C1
Biological process TNFα (P value) Control C1 (P value) ID (term GO)
Positive regulation of GTPase activity 1.76 × 10−20 2.65 × 10−01 GO:0043547
Cellular response to tumor necrosis factor 2.75 × 10−22 3.52 × 10−01 GO:0071356
Granulocyte chemotaxis 1.49 × 10−27 1.04 × 10−09 GO:0071621
Positive regulation of ERK1 and ERK2 cascade 3.34 × 10−19 4.51 × 10− 01 GO:0070374
Cytokine-mediated signaling pathway 6.74 × 10−29 1.32 × 10−07 GO:0019221
Inflammatory response 1.88 × 10−24 1.28 × 10−03 GO:0006954
Antimicrobial humoral immune response mediated by antimicrobial peptide 6.43 × 10−03 – GO:0061844
Cellular response to lipopolysaccharide 1.18 × 10−02 3.24 × 10−04 GO:0071222
MAPK cascade 3.42 × 10−10 3.45 × 10−02 GO:0000165
Innate immune response 7.55 × 10−09 – GO:0045087
Analysis of data using the PANTHER classification system obtained with a cytokine array in the culture media. The corresponding P value is shown according to
the binomial test. The identity (ID) of the gene products (GO terms from PANTHER GO slim) describing the function is indicated
Table 4 Upregulated proteins secreted by BM-MSC under TNFα stimulation compared with control C1
Protein Biological processes Abundance ratio (sample/Control C1) P value
C-X-C motif chemokine 3 1, 2, 3, 4, 5 11.38 1 × 10−1
C-type lectin domain family 4 member E 3,4, 5, 6 8.464 1 × 10−17
Platelet factor 4 1, 3, 4, 7 5.818 5.54 × 10−10
C-X-C motif chemokine 10 1, 3, 4, 5 5.198 2.44 × 10−12
Pentraxin-related protein PTX3 3, 4, 5 4.613 5.66 × 10−11
Stromelysin-1 4, 5, 8 3.936 4.98 × 10−09
Isoform 2 of sequestosome-1 4, 5, 6, 7, 8, 9, 10 3.842 9.45 × 10−09
Neutrophil gelatinase-associated lipocalin 3, 4, 5, 7, 9, 10, 11 3.267 0.0002
CD82 antigen 4, 5 2.869 3.98 × 10−05
Tumor necrosis factor receptor superfamily member 1B 3, 4, 5, 12, 13 2.762 0.0006
Copper transport protein ATOX1 2, 5, 11 2.572 7.45 × 10−05
Prostaglandin G/H synthase 2 3, 4, 5, 6, 8 2.421 0.005
Intercellular adhesion molecule 1 1, 2, 3, 4, 5, 7, 9 2.107 0.002
GRIP1-associated protein 1 4, 8, 11 2.023 0.02
MAGUK p55 subfamily member 6 8 2.013 0.03
Mass spectrometry analysis of secretome. The P value is calculated in a background-based ANOVA. This method uses the background population of ratios for all
peptides and proteins to determine whether any given single peptide or protein is significantly changing relative to that background. Biological processes: 1,
cellular component movement; 2, cellular homeostasis; 3, defense response; 4, regulation of biological process; 5, response to stimulus; 6, cell differentiation; 7,
cell organization and biogenesis; 8, metabolic process; 9, cell communication; 10, cell death; 11, transport; 12, cell proliferation; 13, development. More data of
these proteins is shown in Additional file 5
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been suggested that the host environment of the devel-
oping brain allows the transdifferentiation of MSC [52,
53]. Also, MSC have been suggested capable of stimulat-
ing neurogenesis and formation of new astrocytes or oli-
godendrocytes [54, 55]. In the present study, BM-MSC
were integrated into the periventricular walls of hyh
mice keeping the expression pattern for nestin, GFAP,
NG2, β-III tubulin, Olig2, and NeuN. Furthermore, the
molecular and cellular analysis in hydrocephalic hyh
mice treated with BM-MSC did not reveal any increase
of neural cells. Therefore, the present results have shown
that injected BM-MSC remained as stem cells without
undergoing into transdifferentiation.
Neuroprotective effect of BM-MSC in hydrocephalic mice
In hydrocephalic hyh mice treated with BM-MSC, the
reduction in the number of apoptotic cells, and the de-
creased levels of neurocytotoxic metabolites and osmo-
lytes suggest the induction of a neuroprotective
environment. As discussed above, the protection would
exclude cell replacement. Therefore, the effect could be
through the production of growth factors or cytokines,
vascular effects, reduction of oxidative stress, and modu-
lation of the inflammatory response, as it has been de-
scribed in other experimental treatments [11, 15, 50].
Because a heterogeneous population has been trans-
planted to hydrocephalic hyh mice, more than one effect
is expected. In this way, 10% of MSC were positive for
CD11b, a molecule that inhibits TLR-induced inflamma-
tory responses by the inhibition of inflammatory cyto-
kines (IL-6 and TNFα) and increasing anti-inflammatory
cytokine (IL-10 and TGF-β) production in microglia
[56]. This suggests that part of the transplanted cells
could have an anti-inflammatory role.
In addition, in the present investigation, it has been
found that transplanted BM-MSC express the neuro-
trophic factors GDNF, BDNF, NGF, and VEGF, which
have been implicated in increasing neuronal survival and
in reducing apoptosis [13, 15, 48, 57–61]. The produc-
tion of these factors could also be increased in hypoxic
conditions [62], which could be present in the hydro-
cephalic hyh mice with high intracranial pressure [30].
BDNF secreted by MSC could also protect neurons from
glutamate excitotoxicity by reducing neuronal sensitivity
to glutamate [63]. However, it is unlikely that bioactive
factors released by local BM-MSC per se were the only
and direct contributors to the improvement of neuro-
logical deficits [48]. Interestingly, BM-MSC could acti-
vate astrocytes to release neurotrophic factors, such as
GDNF or TNFα, which would promote and facilitate tis-
sue recovery [48, 60]. TNFα could also stimulate the
production of paracrine factors such as VEGF [62].
TNFα has been found produced by periventricular react-
ive astrocytes in the hyh mouse and human fetuses with
hydrocephalus [43]. VEGF and GDNF expressions have
been also found in these reactive astrocytes (unpublished
observations, and see GDNF immunostaining in Fig. 2f).
VEGF is one of the most effective trophic factors indu-
cing angiogenesis, thus contributing to the recovery of
ischemic conditions [64–66]. The secretion of these
neurotrophic factors by BM-MSC and the neighbor re-
active astrocytes could create an optimal environment.
Further studies are needed to know the mechanisms be-
hind the action of the neurotrophic factors.
In the present study, the secretome analysis of BM-
MSC licensed with TNFα points to some mechanisms
that can be implicated in the brain parenchyma recover-
ing. In this way, lipocanin-2 has been described stimu-
lated by TNFα and involved in anti-inflammatory
responses [67]. ATOX1 is anti-oxidant and anti-
inflammatory [68]. Pentraxin-3 has also been found up-
regulated in our experiments. Previous studies described
Pentraxin-3 as a factor that promotes recovery in neural
tissue after ischemia [69]. The secretion of the TIM-1
and CXCL16 has been found implicated in tissue recov-
ery mediated by endothelial cells [70]. VEGF has also
been proved implicated in tissue recovery mediated by
increased permeability of the blood-brain barrier [71].
Therefore, the secretion of several proteins was upregu-
lated after TNFα stimulation. These proteins could cause
neuroprotection and explain the positive effects on the
metabolite levels found in the present investigation dis-
cussed below.
Recovering metabolite concentrations in the neocortex of
hydrocephalic hyh mice treated with BM-MSC
Several metabolites are present in high concentrations in
the neocortex of hydrocephalic hyh sham-injected mice,
probably as a consequence of periventricular edema, is-
chemia, and degenerative conditions [30]. These levels
reported here are similar to those previously described
in hydrocephalic hyh mice with severe hydrocephalus in
the absence of surgery or treatment [30]. Comparatively,
the levels of these metabolites in hydrocephalic hyh mice
treated with BM-MSC for 4 days are reduced enough to
resemble those of non-hydrocephalic mice.
Metabolite/osmolyte reduction can represent a recov-
ering in the environment of the damaged neocortex.
One of the significant metabolites is creatine, which has
been related to neuroprotective effect against ischemic
damage as phosphocreatine allows ATP synthesis in the
absence of glucose or oxygen [72]. Another key metabol-
ite is glutamate. In astrocytes, through glutamate de-
hydrogenase, glutamate contributes to the tricarboxylic
cycle intermediate α-ketoglutarate and ATP production
after brain ischemia [73]. Extracellular presence of glu-
tamate is excitotoxic since it provokes the activation of
glutamate receptors in the post-synaptic membrane,
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leading to the destruction of the calcium buffer
system, mitochondria damage, and inhibition of
phosphatidylcholine-specific phospholipase C [74].
High levels of glutamate in the interstitial fluid can
be a consequence of neural or glial destruction [74].
In hydrocephalic hyh mice treated with BM-MSC,
glycine, phosphatidylethanolamine, taurine, and threo-
nine, which are considered osmoregulatory metabo-
lites [75, 76], were found following the same trends
as glutamine and glutamate. Phosphatidylethanolamine
and taurine are regulatory osmolytes that have been
related to brain injury [77]. N-acetyl-aspartate is a
marker of neuronal activity that is usually used to de-
termine neuronal density in NMR spectroscopy. In
hydrocephalic hyh mice treated with BM-MSC, the
levels of N-acetyl-aspartate are lower than in hydro-
cephalic hyh sham-injected mice. However, the ana-
lysis of neuronal density in the neocortex of both
groups of hydrocephalic hyh mice has shown no dif-
ference. N-acetyl-aspartate is also considered an
osmolyte required for myelination [78], and their
lower levels in hydrocephalic hyh mice treated with
BM-MSC could be a consequence of clearance in the
periventricular edema.
Conclusions
BM-MSC can integrate into the neocortical walls of the
lateral ventricles of hydrocephalic hyh mice with severe
hydrocephalus without rejection, remaining undifferenti-
ated and integrated among reactive astrocytes in the
periventricular regions. The neocortical tissue, after the
BM-MSC therapy, showed signs of recovery, detected as
a reduction of apoptosis and in reduced levels of
hydrocephalic-associated metabolites/osmolytes. The ex-
perimental approach, including analysis of metabolite
spectra with NMR, used in this work makes these find-
ings transferable to the human clinic. Therefore, admin-
istration of BM-MSC seems to be a promising stem cell
therapy for the treatment of neurodegenerative condi-
tions present in severe obstructive hydrocephalus.
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